InClin CEO and leadership

George Faurot is a Chief Operating Officer at Inclin Inc and is based in Los Altos, California. He has worked as Clinical Research Associate at Syntex Development Research, Palo Alto, CA; Senior Clinical Research Associate/Clinical Program Manager at Oculex Pharmaceuticals, Inc., Sunnyvale, CA; and CRA / Biologist at SYNTEX INC. George attended UC Davis between 1986 and 1988.

Over 30 years of executive leadership and management experience in international commercial drug development (Phase I-III), drug discovery, preclinical translational and clinical medicine, clinical pharmacology, and commercial development strategy and risk management. Skills/Experience Areas:Drug Development (International Phase I, II & III trials)Clinical trial design (Phase I-III), implementation and conductTrial feasibility and logistics - enrollment, regulatory requirements and optimizationIND/IMPD/CTN preparation CRO selection, contracting, managementRelevant Preclinical Translational Medicine and Science to Support FIH/Phase I Dosing & Development FIH Dose Calculations including MABEL, and Dose Escalation: Analysis & JustificationImmuno-oncology therapeutics: ADCs, CPIs, Agonists, BiTEs, cytokines, othersTargeted therapies - eg., TKIs (eg., EGFR, ALK, ROS1, cMET, KRAS, ERBB2)Small molecules - cytotoxicsCAR-T, allogeneic, autologous transplantationSupportive care therapiesTerritories: US, China, EU, Eastern Europe, Japan, S. Korea, Taiwan and AUSICH GCP compliance including risk assessment, management, and oversightDrug safety reporting & compliance; Argus multi-tenant enterprise configuration and validationPharmacology (preclinical & clinical) KOL network recruitmentRegulatory & commercial product development strategy: feasibility & risk mitigationClinical & laboratory medical forensicsCorporate governance, structure and negotiation of transactions, & corporate performanceCorporate strategy, finance, private equity, strategic alliances, joint ventures, NPV/DCF, & licensing Patents (compositions of matter, formulation, methods of use, process)/inventorship, patent exclusivity, due diligence - pharmaceutical and biotechnology.